Navigation Links
Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings

SUNNYVALE, Calif., May 18, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that a clinical abstract on our Btk inhibitor, PCI-32765, has been selected for an oral presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011 in Chicago, IL. Additionally, two clinical abstracts on PCI-32765 have been selected for oral presentations at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, June 15-18, 2011.

Pharmacyclics plans to present a material update on the PCI-32765 clinical development program in a press release after the ASCO oral presentation on Monday, June 6, 2011 and expects to hold a conference call as well. The update will encompass the entire PCI-32765 clinical development program and will specifically include: 1) safety and efficacy data with the use of single-agent PCI-32765 in relapsed/ refractory or treatment-naive chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL) in patients with adequate follow-up from our ongoing Phase IB/II trial, including patients with poor-risk disease; 2) an update of efficacy from the Phase 1A trial of PCI-32765 in B-cell malignancies, including mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma and 3) a status update for ongoing PCI-32765 clinical studies, including  a pilot trial of PCI-32765 in the ABC subtype of diffuse large B-cell lymphoma, a phase II trial of single agent PCI-32765 in mantle cell lymphoma, and studies with PCI-32765 in combination with either bendamustine/rituximab (BR), fludarabine/cyclophosphamide/rituximab (FCR), or ofatumumab in CLL. Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)Abstract #6508Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PMSession Title: Leukemia, Myelodysplasia and TransplantationLocation: Arie Crown TheaterOral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)Abstract # 122Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study.  S. O'Brien et al. Date/Time: Friday, June 17, 2011; 9:45 AMSession 10: Chronic Lymphocytic Leukemia (CLL)Location: Room A, B, C and Marquee Parco Ciani)Abstract # 153Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study.  R.H. Advani et al.Date/Time: Saturday, June 18, 2011; 9:30 AMSession 14:  Signaling Pathways in LymphomaLocation: Room AAbout PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has four product candidates in clinical development and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.

The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at


SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
2. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
3. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
4. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
5. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
6. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
7. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
8. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
9. Pharmacyclics Reports Second Quarter Fiscal 2010 Financial Results
10. Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
Breaking Medicine Technology:
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved around ... help protect a patient’s overall health. The talk stressed the link between periodontal disease ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of ... in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately ... nationally, through a vast social media strategy and across a network of top ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):